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Open acceAbstract Objective: Neoadjuvant chemotherapy (NACT) for cervical cancer still remains
controversial. NACT was evaluated to establish selection criteria.
Methods: A matched-case comparison was designed for the NACT group (n = 707) and pri-
mary surgery treatment (PST; n = 707) group to investigate short-term responses and high/
intermediate risk factors (HRFs/IRFs). The 5-year disease-free survival (DFS) and overall
survival (OS) rates were stratiﬁed by NACT response, HRFs/IRFs, International Federation
of Gynecology and Obstetrics (FIGO) stage and tumour size, respectively.15
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2354 T. Hu et al. / European Journal of Cancer 48 (2012) 2353–2360Results: The clinical and pathological response rates were 79.3% and 14.9% in the NACT
group. In comparison to the PST group, IRFs but not HRFs were signiﬁcantly decreased
(P < 0.05), and the 5-year DFS rate was signiﬁcantly improved in the NACT group (88.4%
versus 83.1%, P = 0.021). Moreover, the 5-year DFS and OS rates were favourably increased
in the clinical responders in comparison to the PST group and the clinical non-responders
(P < 0.05). Compared to those of clinical non-responders, the 5-year DFS and OS rates of
clinical responders, with or without HRFs, were also signiﬁcantly increased (P < 0.01). In
stage IB2, the 5-year DFS and OS rates were signiﬁcantly increased, whereas operation dura-
tion declined in the NACT group (P < 0.05). For patients with stage IB tumours of 2–5 cm,
the 5-year DFS and OS rates of clinical responders were signiﬁcantly improved (P < 0.05).
Conclusions: NACT is a suitable option for patients with cervical cancer, especially for NACT
responders and patients with stage IB, which provides a new concept of fertility preservation
for young patients.
 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Cervical cancer is still the second most common
malignancy and second most common cause of cancer-
related death in women worldwide.1 Approximately
15% of all cervical cancers occur in women under the
age of 40.1,2 Traditional treatment for cervical cancer
consists of radical surgery or radiotherapy; however,
neither method spares fertility, and either can lead to
psychosexual dysfunction and decreased quality of life.
This issue is becoming more critical because an increas-
ing number of cervical cancers are diagnosed in nullipa-
rous patients of reproductive age. Over the past decade,
the treatment of cervical cancer has placed an increased
emphasis on fertility preservation, prompting the ques-
tion of whether it is possible to preserve genital func-
tions without increasing the risk of recurrence,
aﬀording patients the opportunity to bear children.
Neoadjuvant chemotherapy (NACT) prior to surgery
is an alternative option that does not aﬀect genital func-
tions. Successful pregnancy following NACT demon-
strates that NACT and adjuvant chemotherapy do not
always aﬀect fertility or eliminate the chance for preg-
nancy. The ability of NACT to reduce tumour volume
and virtually sterilise micrometastases may be due to
an uncompromised tumour blood supply and a popula-
tion of chemosensitive tumour cells. Thus, NACT
allows for a less-extensive dissection of the cervix instead
of radical hysterectomy while preserving the eﬀective-
ness of the treatment.3,4
Despite high response rates, the use of NACT for cer-
vical cancer treatment still remains controversial.5–7 In
part, this is due to the fact that patient responses to
NACT were both positive and detrimental (increased
or decreased survivals). However, the discrepancies in
these ﬁndings are likely due to patient selection, NACT
scheme and length of NACT treatment.8,9 NACT fol-
lowed by surgery is regarded as an eﬀective option and
also provides opportunities of fertility-sparing treatment
for patients with International Federation of Gynecol-
ogy and Obstetrics (FIGO) stage IB-IIA tumours of>2 cm.10,11 However, various risk factors have been
shown to contribute to disease recurrence and cancer-
related death following NACT treatment.12,13 It remains
unknown whether the clinical and pathological risk
factors were signiﬁcantly decreased after NACT.
Therefore, correlations between these risk factors,
chemoresponsiveness and patient outcomes require fur-
ther investigation.
In this study, we explored short/long-term outcomes,
chemoresponsiveness and risk factors to identify beneﬁ-
cial characteristics that may help predict a positive
response to NACT treatment in patients with FIGO
stage IB1-IIB cervical cancer in order to establish selec-
tion criteria, especially for fertility preservation.2. Materials and methods
2.1. Patients
Clinical data from 10,897 patients was recruited from
the cervical cancer database v1.10 (http://clinicaltri-
als.gov; NCT01267851). This study was reviewed by
the Ethics Committee of Huazhong University of Sci-
ence and Technology, and informed consent was
obtained from each patient.
The inclusion criteria were as follows: patients with
FIGO stage IB1-IIB cervical cancer (squamous, adeno-
or adenosquamous and small cell carcinoma)14; patients
treated with or without NACT followed by radical hys-
terectomy and bilateral pelvic lymphadenectomy;
patients who did not receive primary radiotherapy, pre-
operative radiotherapy or concurrent chemoradiother-
apy and patients with no existing complicating disease
or prior malignant disease.
Three thousand eight hundred and ninety six patients
with FIGO stage IB1-IIB were treated with or without
NACT from January 2002 to December 2008. Gener-
ally, the mean tumour size and the percentage of
patients with stage IIB in the NACT group were larger
than that in the primary surgery treatment (PST) group
T. Hu et al. / European Journal of Cancer 48 (2012) 2353–2360 2355(4.1 ± 1.3 versus 2.9 ± 1.3, P < 0.001; 31.8% versus
5.8%, P < 0.001). To eliminate bias, a matched case–
control study (1:1) for age at diagnosis, FIGO stage,
tumour size (cm) and histological type was designed to
evaluate the eﬃcacy of NACT (Fig. S1). All patients
received radical hysterectomy with pelvic lymphadenec-
tomy, and para-aortic lymphadenectomy was performed
in patients with suspicious para-aortic lymph node
metastasis.2.2. NACT treatment
Cisplatin-based chemotherapy was the standard
treatment for NACT in this study, and the NACT regi-
mens used in our study were shown in Table S1. NACT
was generally administered in 1–2 courses depending on
tolerance and response (n = 648; 91.65%), and small
amount of patients received additional 1–2 cycles
(n = 16, 2.26%). The maximal duration was no more
than 60 days to avoid a delay in curative treatment.
For the fertility-sparing option, 1–2 courses of NACT
were followed by less-extensive surgery and two or more
courses of adjuvant chemotherapy.2.3. Evaluation of short-term response
In accordance with the World Health Organization
(WHO) criteria, the clinical response to NACT was eval-
uated at the initial diagnostic procedure and before sur-
gery.15 A complete response (CR) was deﬁned as the
complete disappearance of all clinically detectable dis-
ease. A 50% or more decrease in tumour size constituted
a partial response (PR). Stable disease (SD) was deﬁned
as less than 50% reduction in tumour size, and progres-
sive disease (PD) was regarded as an increase of tumour
volume or appearance of new lesions. NACT responders
were deﬁned as the patients with CR or PR, and NACT
non-responders included patients with SD or PD. Path-
ological optimal response (pOR) was deﬁned as com-
plete disappearance of tumour(s) in the cervix with
negative nodes (pCR) or residual disease with less than
3 mm stromal invasion (PR1). Pathological suboptimal
response included persistent residual disease with more
than 3 mm stromal invasion on the surgical specimen
(PR2). Two pathologists participated in the pathological
evaluation.2.4. Evaluation of high-risk factors (HRFs) and
intermediate-risk factors (IRFs)
HRFs and IRFs were evaluated after surgery. HRFs
included positive lymph nodes, positive resection margin
and parametrial invasion.16 IRFs included large tumour
size (the longest diameter on a surgical specimen >4 cm)
and lymphovascular space invasion (LVSI) (>1/3 stro-
mal invasion).172.5. Follow-up study
Follow-up examination for all patients was suggested
to be every three months for the ﬁrst year and every
6 months for the next four years. In our database, fol-
low-up was not feasible for a small proportion of
patients due to loss of contact, and these data were
excluded from the survival analysis.2.6. Statistical analysis
Age at diagnosis (year), tumour sizes (cm), operation
duration (hour) and blood loss volume (ml) were com-
pared in the NACT and PST groups with Student’s t-
test. In the clinical and pathological response analysis,
the association between NACT eﬃcacy and several
clinical characteristics (FIGO stage, tumour size and
histological types) were evaluated using the Pearson
chi-squared test with linear-by-linear association. Other
statistical analyses of frequency data were performed via
the chi-squared test or Fisher exact test. Disease-free
survival (DFS) and overall survival (OS) were estimated
by Kaplan–Meier analysis. The log-rank test was used
to compare survival curves.
Statistical analyses were performed by using SPSS
13.0 software package. Values are presented as
mean ± standard deviation unless otherwise noted. Sta-
tistical tests were considered signiﬁcant when P values
were less than 0.05.3. Results
3.1. Patient characteristics
The stratiﬁed characteristics in the NACT group
(n = 707) and the PST group (n = 707) were well-
matched (Table S2). The follow-up rate was 78.4%
(1108/1414), and the median follow-up time was
38 months (range, 4–108).3.2. Short-term responses to NACT
A clinical response occurred in 79.3% (541/682) of
patients, including 12.6%, (86/682) CR and 66.7%
(455/682) PR, and the pathological response was
14.9% (105/707) (Table S3). Moreover, better clinical
response was observed in patients with earlier FIGO
stage or smaller tumour size (P < 0.001; Table 1).
Reduced IRFs were clearly detected in the NACT
group compared to the PST group (P < 0.01, respec-
tively; Table 2), especially for patients with FIGO stage
IB1, with a tumour size of 64 cm, and with squamous
cell carcinoma (Table 2). However, a decrease in HRFs
was not detected after NACT, even in subpopulations
stratiﬁed by FIGO stage, tumour size or histological
type (P > 0.05; Table 2). For patients with bulky
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was signiﬁcantly decreased after NACT (P < 0.001;
Table 2).3.3. Long-term survival analysis
Matched case–control comparison (417/417) was per-
formed to evaluate long-term survival, and patients
without follow-up data and their matched cases were
excluded. The 5-year DFS rate in the NACT group
was signiﬁcantly improved in comparison to the PST
group (88.4% versus 83.1%; P = 0.021), whereas there
was an increasing trend of 5-year OS rate (P = 0.075;
Fig. 1A and B). Compared with the PST group, the
mortality (7.4% versus 11.5%; P = 0.044) and recurrence
(9.6% versus 15.3%; P = 0.012) rates were decreased in
the NACT group.
To analyse the clinical response to NACT, patients in
the NACT were divided into a clinical responder sub-
group (n = 330) and a clinical non-responder subgroup
(n = 76), while the response of 11 patients remained
unknown. Compared with patients in the PST groups
and the clinical non-responder subgroup, the clinical
responder subgroup displayed favourably increased
DFS and OS rates (P < 0.05; Fig. 1C and D). The poorest
outcomes were observed in the clinical non-responder
subgroup, with a 70% 5-year DFS rate and a 68.9%
5-year OS rate (P < 0.05; Fig. 1C and D).
Next, patients in the NACT and PST groups were fur-
ther stratiﬁed by HRFs or IRFs, respectively. The 5-year
DFS and OS rates of NACT responders, with or without
HRFs, were signiﬁcantly increased over those of the
NACT non-responders (P < 0.01; Fig. S2C and D).
Alternatively, neither the 5-year DFS rate nor the 5-year
OS rate signiﬁcantly diﬀered among four subgroupsTable 1
Clinical and pathological response to NACT for patient subgroups stratiﬁ
Number CR PR SD + PD Unk
FIGO stage
IB1 127 36 72 19 0
IB2 205 20 140 40 5
IIA1 85 14 50 16 5
IIA2 162 9 112 37 4
IIB 128 7 81 29 11
Tumour size (cm)
64 cm 305 55 181 55 14
>4 cm 402 31 274 86 11
Histological typesb
Squamous cell carcinoma 638 76 411 129 22
Adenocarcinomac 67 10 43 11 3
Abbreviations: NACT, Neoadjuvant chemotherapy; FIGO, International F
partial response; SD, stable disease; PD, progressive disease; pOR, pathol
a P values were calculated with linear-by-linear association chi-square te
b Small cell carcinoma was excluded in the histological type analysis bec
c Adenocarcinoma and adenosquamous carcinoma were included, the
calculation of percentage of response rate.stratiﬁed by IRFs (P > 0.05; Fig. S3A-B). The prognosis
in NACT non-responders with <2 IRFs was the poorest
of the four subgroups, with a 73.4% 5-year DFS rate and
a 71.8% 5-year OS rate, both of which signiﬁcantly dif-
fered from the NACT responders with <2 IRFs
(P < 0.001; Fig. S3C and D).
In FIGO stage IB2, the 5-year DFS and OS rates
were signiﬁcantly increased in the NACT group com-
pared to those of the PST group (P = 0.015 and 0.044;
Fig. 2), whereas the mortality (4.1% versus 11.0%;
P = 0.027) and recurrence (4.1% versus 12.3%;
P = 0.011) rates, operation duration (mean value, 3.6 h
versus 3.8 h; P < 0.05) and blood loss volume (mean
value, 517 ml versus 559 ml; P = 0.145) were decreased.
Moreover, the 5-year DFS and OS rates of clinical
responders were signiﬁcantly improved compared to
those in the PST and clinical non-responder subgroups
for patients with tumours of 2–5 cm in FIGO IB
(P < 0.05, Fig. 3), whereas the mortality (3.9% versus
10.8% versus 17.2%; P = 0.015) and recurrence rates
(5.2% versus 15.6% versus 17.2%; P = 0.006) were dis-
tinctly decreased.3.4. Representative NACT cases followed by the fertility-
sparing option
A 31-year-old G2P0A2 patient desiring fertility pres-
ervation was diagnosed with FIGO stage IA1 cervical
cancer in 2007. Following a course of TP regimen
NACT, a simple trachelectomy and laparoscopic pelvic
lymphadenectomy were performed, and all lymph nodes
were found to be negative (0/30). Subsequently, two
courses of TP regimen chemotherapy were applied.
The patient conceived naturally 19 months after surgery
and delivered by caesarean section at 37+2 weeks. Theed by tumour size, FIGO stage and histological type.
nown CR + PR pOR
Number % P valuea Number % P valuea
108 85.0 0.04 41 32.3 <0.001
160 80 28 13.7
64 80 14 16.5
121 76.6 9 5.6
88 75.2 13 10.2
236 81.1 0.32 63 20.7 <0.001
305 78.0 42 10.4
487 79.1 0.48 95 14.9 0.99
53 82.8 10 14.9
ederation of Gynecology and Obstetrics; CR, complete response; PR,
ogical optimal response.
st.
ause of the limited sample number.
patients with unknown clinical responses were not included in the
Table 2
Eﬀects of NACT on risk factors in the patient subgroups.
Tumour size > 4 cm LVSIa >1/3 stromal invasion Lymph node metastasis Parametrial invasion Positive surgical margin
No. P valueb No. P valueb No. P valueb No. P valueb No. P valueb No. P valueb
Overall
NACT (n = 707) 86 <0.001 59 0.002 294 0.001 140 0.082 43 0.339 19 0.289
PST (n = 707) 402 95 355 167 52 26
FIGO stage
IB1
NACT (n = 127) – 6 0.006 19 0.029 14 0.079 3 0.723 1 1.000
PST (n = 127) – 19 33 24 4 0
IB2
NACT (n = 205) 37 <0.001 13 0.842 80 0.194 35 0.138 8 0.793 5 0.724
PST (n = 205) 205 14 93 47 7 3
IIA1
NACT (n = 85) – 12 0.308 46 0.758 17 0.362 2 1.000 4 1.000
PST (n = 85) – 17 48 22 3 4
NACT (n = 162) 41 <0.001 19 0.413 77 0.095 39 0.896 7 0.777 4 0.257
PST (n = 162) 162 24 92 38 6 9
IIB
NACT (n = 128) 8 <0.001 9 0.020 72 0.028 35 0.889 23 0.171 5 0.287
PST (n = 128) 35 21 89 36 32 10
Tumour size
64 cm
NACT (n = 305) – 26 0.003 114 0.011 57 0.094 21 0.238 9 0.505
PST (n = 305) – 50 145 74 29 12
>4 cm
NACT (n = 402) – 33 0.153 180 0.034 83 0.394 22 0.878 10 0.407
PST (n = 402) – 45 210 93 23 14
Histological typesc
Squamous cell carcinoma
NACT (n = 638) 77 <0.001 52 0.002 269 0.002 125 0.067 38 0.264 19 0.438
PST (n = 638) 363 86 324 152 48 24
Adenocarcinoma d
NACT (n = 67) 9 <0.001 7 0.784 25 0.380 15 0.834 5 0.718 0 0.496
PST (n = 67) 38 8 30 14 3 2
Abbreviations: NACT, Neoadjuvant chemotherapy; PST, primary surgery treatment.
a LVSI, lymphovascular space invasion.
b P values were calculated with Pearson chi-square test or Fisher exact test.
c Small cell carcinoma was excluded in the histological type analysis because of the limited sample numbers.
d Adenocarcinoma and adenosquamous carcinoma were included.
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Fig. 1. Long-term outcomes in the NACT and the PST groups with or without clinical response. (A–B): Comparison of DFS and OS between the
NACT group (n = 417) and the PST group (n = 417). (C–D): Comparison of DFS and OS in the NACT clinical response subgroup (n = 330), the
NACT clinical non-response subgroup (n = 76), the PST group (n = 417).
2358 T. Hu et al. / European Journal of Cancer 48 (2012) 2353–2360newborn exhibited no evidence of abnormalities, with an
Apgar score of 8/9, and was completely normal after
43 months. Another 28-year-old G2P0A2 woman was
diagnosed with FIGO stage IA2 cervical cancer in
2005. After one cycle of CP regimen NACT, large colo-
nisation was undertaken, followed by two courses of TP
regimen chemotherapy. The patient conceived naturally
after 20 months and delivered a 3300-g female with an
Apgar score of 8/9 via caesarean section at 39+1 weeks.
Throughout the 67-month follow-up, the mother
remained disease-free and the child was developing
normally.4. Discussion
In this study, NACT displayed eﬃcient short-term
responses, whereas clinical and pathological responses
increased along with a reduction in tumour size and
FIGO stage. Also, the decrease observed in IRFs was
found to be signiﬁcant. Previously, lymph node metasta-
sis (LNM) was accepted as the most important adverse
prognostic factor for cervical cancer.18 However, the inci-
dence of LNM, parametrial invasion and positive surgi-
cal margin was slightly lower after NACT in this study
(P > 0.05). These observations suggest that HRFs are
not predominantly inﬂuenced by NACT in the short-
term.
Generally, NACT treatment signiﬁcantly improved
the 5-year DFS rate, whereas the mortality and recur-
rence rates decreased. Further analysis revealed thatthe 5-year DFS and OS rates of NACT responders were
increased, whereas those of NACT non-responders were
dramatically worse. These observations may be directly
correlated with chemoresponsiveness, operability and
outcomes in cervical cancer.19 Thus, the clinical
response to NACT may be a signiﬁcant prognostic fac-
tor of survival, which provides meaningful and rapid
information about the eﬃcacy of treatment that can be
used by the patient and clinician to follow, or renounce,
a conservative strategy.
Several studies have explored NACT eﬀectiveness,
alone, in patients with HRFs, although no clear consen-
sus has emerged.20,21 Here, we found that the 5-year DFS
and OS rates greatly improve in patients with or without
HRFs in the NACT responder subgroups compared to
those in NACT non-responder subgroups. Similarly, 5-
year DFS and OS rates of the NACT responders with
<2 IRFs were also increased. These observations suggest
that chemoresponsiveness prior to HRFs and IRFs is
more important for NACT long-term outcomes. Addi-
tionally, the poorest outcome was observed in NACT
non-responders with <2 IRFs subgroup but not in
NACT non-responders with P2 IRFs subgroup. It was
previously reported that NACT could make a small
metastasis hard to detect by making a tumour smaller,
resulting in poor outcomes of patients with fewer IRFs.21
Therefore, this harmful, concealing eﬀect of NACT may
negate the beneﬁcial eﬀects of NACT.
It is important to establish selective criteria for
patients who would beneﬁt most from NACT, especially
Fig. 2. Comparison of DFS and OS rates for locally advanced cervical cancer patients in the NACT groups (stage IB2, n = 146; stage IIA2, n = 87;
stage IIB, n = 66) and matched PST groups.
Fig. 3. Comparison of DFS and OS rates for patients with FIGO IB tumours of 2–5 cm in the NACT with or without clinical response (n = 154;
n = 29) and the PST subgroups (n = 186).
T. Hu et al. / European Journal of Cancer 48 (2012) 2353–2360 2359young patients who desire to preserve fertility. Firstly,
NACT is beneﬁcial to a majority of clinical responders
because of its high clinical response rate, even for
patients with HRFs and IRFs. The short-term responses
to NACT should be regarded as an important prognos-
tic factor for survival. NACT non-responders are
unsuitable for NACT followed by fertility-sparing
options. Secondly, NACT enhances the long-term out-
come for patients with bulky tumours, especially for
FIGO IB2. In this study, the 5-year DFS and OS rates
were distinctly increased, whereas the mortality and
recurrence rates declined. At the same time, operation
duration and blood volume were decreased because of
the reduction in tumour size after NACT. Therefore,patients with FIGO IB2, especially NACT responders,
greatly beneﬁt from NACT. Furthermore, NACT
improves operability for patients with bulky tumours
in FIGO IIA2 and IIB by decreasing tumour size
(Table 2), providing proper treatment for inoperable
patients. Finally, appropriate candidates for fertility-
sparing surgery generally include patients with FIGO
stages IA1, IA2 and IB1 tumours of less than 2 cm
only.22,23 In this study, the long-term outcomes of
NACT clinical responders were signiﬁcantly improved
in IB tumours, 2–5 cm in size, whereas the mortality
and recurrence rates were also distinctly decreased.
According to the principle of NACT followed by fertil-
ity-sparing surgery plus adjuvant chemotherapy, it is
2360 T. Hu et al. / European Journal of Cancer 48 (2012) 2353–2360possible to meet the more extensive requirements of
patients with larger tumours. Adjuvant chemotherapy
may be helpful because the harmful concealing eﬀects
of NACT could make pathological risk factors unde-
tected after surgery in partial patients.21
Although our investigation is still limited by a lack of
prospective randomisation and multicentre veriﬁcation,
the current study suggests that NACT may be a success-
ful treatment option for patients with invasive cervical
cancer. Fertility preservation for young patients is deﬁ-
nitely possible after induction NACT and fertility-spar-
ing surgery, aﬀording a better quality of life and
preserving fertility without worsening the prognosis.
Although very preliminary, our results open the way
to a new concept in the management of invasive cervical
cancer in young women desiring to preserve fertility.
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